Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba

Bigfoot Biomedical and Abbott partner to use “next-generation” FreeStyle Libre glucose monitoring sensor (no fingersticks needed) with Bigfoot’s automated insulin...

How do I stay in range while sleeping?

Novo Nordisk’s newest insulin receives EMA approval; expected to launch in the first half of 2017

Instead of “avoid long-term complications,” Adam Brown focuses on something more motivating and uplifting

Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits

Amalgam Rx receives FDA clearance for basal insulin dosing app, iSage Rx; available with a prescription to adjust Lantus, Levemir, Toujeo, Tresiba, and Basaglar

Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA

Faster version of Novo Nordisk’s NovoLog approved in the US for type 1 and type 2 diabetes, launch expected as early as end of 2017

Ease, comfort, and actionable patterns, but some challenges with insurance coverage

The new blood glucose meter features less expensive strips, uploads readings to smartphones, and integrates with mySugr

Learn practical tips on taking care of your feet and how to easily make them a part of daily diabetes management

Lilly’s Humalog Junior KwikPen offers 0.5 unit dose increments in prefilled, disposable device – a win for highly insulin sensitive users

Why a good night of sleep transforms Adam Brown's diabetes the next day

Training to be tested in a small group before the full launch starts in June

Full results of DEVOTE study presented at ADA 2017 show that basal insulin Tresiba reduces risk of severe hypoglycemia by 40% (by 53% overnight), in addition to being...

How I avoid highs, prevent lows, and stop blood sugar frustration during exercise

How do I talk to family and friends about diabetes? Is this MY burden to bear? Are loved ones a “diabetes bright spot” or “diabetes police”?

A decision on Novo Nordisk’s faster-acting mealtime insulin is expected in late 2017; also launched in Canada, Germany, and the UK, and coming soon to more European...

The diaTribe Foundation convenes key diabetes experts to discuss glycemic outcomes beyond A1C on July 21, 2017, in Bethesda, MD